Phathom Pharmaceuticals, Inc. (PHAT)
4.66
-0.42
(-8.27%)
USD |
NASDAQ |
Nov 20, 16:00
4.60
-0.06
(-1.29%)
After-Hours: 20:00
Phathom Pharmaceuticals Enterprise Value : 749.39M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 749.39M |
| November 19, 2026 | 783.50M |
| November 18, 2026 | 801.37M |
| November 17, 2026 | 817.62M |
| November 16, 2026 | 848.48M |
| November 13, 2026 | 863.10M |
| November 12, 2026 | 876.91M |
| November 11, 2026 | 880.97M |
| November 10, 2026 | 813.15M |
| November 09, 2026 | 803.81M |
| November 06, 2026 | 797.31M |
| November 05, 2026 | 783.50M |
| November 04, 2026 | 832.24M |
| November 03, 2026 | 837.11M |
| November 02, 2026 | 851.33M |
| October 30, 2026 | 837.11M |
| October 29, 2026 | 876.10M |
| October 28, 2026 | 880.97M |
| October 27, 2026 | 857.42M |
| October 26, 2026 | 853.36M |
| October 23, 2026 | 837.11M |
| October 22, 2026 | 940.26M |
| October 21, 2026 | 941.89M |
| October 20, 2026 | 964.63M |
| October 19, 2026 | 940.26M |
| Date | Value |
|---|---|
| October 16, 2026 | 932.95M |
| October 15, 2026 | 980.06M |
| October 14, 2026 | 971.94M |
| October 13, 2026 | 939.45M |
| October 12, 2026 | 950.01M |
| October 09, 2026 | 959.76M |
| October 08, 2026 | 950.01M |
| October 07, 2026 | 924.02M |
| October 06, 2026 | 921.58M |
| October 05, 2026 | 915.09M |
| October 02, 2026 | 932.95M |
| October 01, 2026 | 945.95M |
| September 30, 2026 | 963.82M |
| September 29, 2026 | 958.86M |
| September 28, 2026 | 958.06M |
| September 25, 2026 | 954.06M |
| September 24, 2026 | 936.44M |
| September 23, 2026 | 928.84M |
| September 22, 2026 | 990.89M |
| September 21, 2026 | 966.07M |
| September 18, 2026 | 968.47M |
| September 17, 2026 | 990.09M |
| September 16, 2026 | 985.28M |
| September 15, 2026 | 1.023B |
| September 14, 2026 | 1.065B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.741B |
| Corcept Therapeutics, Inc. | 6.596B |
| Veru, Inc. | 9.969M |
| Johnson & Johnson | 678.48B |
| Eli Lilly & Co. | 1.313T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.90M |
| Revenue (Quarterly) | 84.72M |
| Total Expenses (Quarterly) | 98.62M |
| EPS Diluted (Quarterly) | -0.1637 |
| Gross Profit Margin (Quarterly) | 78.32% |
| Profit Margin (Quarterly) | -16.40% |
| Earnings Yield | -22.11% |
| Normalized Earnings Yield | -22.11 |